S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

CLSD Clearside Biomedical Inc

0.9278

-0.0483 (-4.95%)

Mar 07 2025 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

01/19/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Charles Deignan

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Clearside Biomedical Charts.

Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Clearside Biomedical Charts.

Clearside Biomedical Inc News

Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD
Thursday 6 March 2025 (4 days ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Monday 24 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Friday 21 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Clearside Biomedical’s Asia-Pacific Partner, Arctic Vision, Announced Acceptance of its New Drug Application for ARCATUS® for Regulatory Review in China for the Treatment of Uveitic Macular Edema
Thursday 20 February 2025 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Thursday 13 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting
Monday 10 February 2025 (4 weeks ago) • GlobeNewswire Inc.

Clearside Biomedical to Participate in Fireside Chat at the Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
Tuesday 4 February 2025 (1 month ago) • GlobeNewswire Inc.

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program
Tuesday 28 January 2025 (1 month ago) • GlobeNewswire Inc.

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore
Wednesday 22 January 2025 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 10 January 2025 (2 months ago) • Edgar (US Regulatory)

Clearside Biomedical Announces Publication of Critical Insights into Retinal Drug Development in the Peer-Reviewed Scientific Journal, Eye
Thursday 19 December 2024 (3 months ago) • GlobeNewswire Inc.

Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States
Monday 25 November 2024 (3 months ago) • GlobeNewswire Inc.

More Clearside Biomedical Inc News Articles

Banque Palatine null

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions